Skip to content

ELOXX PHARMACEUTICALS, INC.: 10-K filed 2014-09-29

What ELOXX PHARMACEUTICALS, INC. reported in its annual report filed 2014-09-29 (fiscal FY 2014): 33 published measures, 84 facts as tagged in accession 0001144204-14-058176.

This filing

Form
10-K (annual report)
Filed
2014-09-29
Fiscal period
fiscal FY 2014
Accession
0001144204-14-058176 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ELOXX PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-06-3033,334,828USD
At 2013-06-307,097,737USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-06-305,844,899USD
At 2013-06-303,311,670USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-06-3027,489,929USD
At 2013-06-303,786,067USD
At 2012-06-303,453,028USD
At 2011-06-304,517,463USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-06-306,111,340USD
At 2013-06-301,602,294USD
At 2012-06-302,001,325USD
At 2011-06-303,609,954USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-07-01 to 2014-06-30-9,225,234USD365
2012-07-01 to 2013-06-30-6,122,542USD365
2011-07-01 to 2012-06-30-5,066,133USD366

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-07-01 to 2014-06-30-4,868,133USD365
2012-07-01 to 2013-06-30-3,902,626USD365
2011-07-01 to 2012-06-30-4,386,049USD366

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2013-07-01 to 2014-06-303,194USD365
2012-07-01 to 2013-06-301,281USD365
2011-07-01 to 2012-06-304,461USD366

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2013-07-01 to 2014-06-30182,229USD365
2012-07-01 to 2013-06-307,819USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-07-01 to 2014-06-308,730,243USD365
2012-07-01 to 2013-06-304,032,637USD365
2011-07-01 to 2012-06-303,227,916USD366

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2013-07-01 to 2014-06-30646,936USD365
2012-07-01 to 2013-06-30-529,042USD365
2011-07-01 to 2012-06-30-450,496USD366

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2014-06-30223,475USD
At 2013-06-304,555USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-07-01 to 2014-06-301,297,224USD365
2012-07-01 to 2013-06-30724,693USD365
2011-07-01 to 2012-06-30766,004USD366

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-07-01 to 2014-06-30-9,147,796USD365
2012-07-01 to 2013-06-30-4,650,500USD365
2011-07-01 to 2012-06-30-5,411,528USD366

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-06-307,224,398USD
At 2013-06-303,521,514USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-06-301,825,171USD
At 2013-06-303,211,942USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2014-06-30901,180USD
At 2013-06-30637,320USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2014-06-3013,902,917USD
At 2013-06-300USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2014-06-302,178,867USD
At 2013-06-303,566,497USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2014-06-3043,133USD
At 2013-06-300USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-07-01 to 2014-06-303,338,687USD365
2012-07-01 to 2013-06-302,086,666USD365
2011-07-01 to 2012-06-302,566,247USD366

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-06-3013,846,361shares
At 2013-06-302,272,062shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2014-06-30115,631,726USD
At 2013-06-3078,189,173USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2014-06-30337,202USD
At 2013-06-30100,008USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2014-06-30113,727USD
At 2013-06-3095,453USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2014-06-302,178,867USD
At 2013-06-303,566,497USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2014-06-3099,728USD
At 2013-06-3099,728USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2014-06-30923,991USD
At 2013-06-30387,540USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2013-07-01 to 2014-06-30-13,854,431USD365
2012-07-01 to 2013-06-30-6,985,540USD365
2011-07-01 to 2012-06-30-6,691,860USD366

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2013-07-01 to 2014-06-30-13,854,431USD365
2012-07-01 to 2013-06-30-6,985,540USD365
2011-07-01 to 2012-06-30-6,691,860USD366

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-07-01 to 2014-06-303,683,350USD365
2012-07-01 to 2013-06-302,499,624USD365
2011-07-01 to 2012-06-302,724,144USD366

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2013-07-01 to 2014-06-3018,275USD365
2012-07-01 to 2013-06-302,583USD365
2011-07-01 to 2012-06-302,386USD366

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2013-07-01 to 2014-06-30331,381USD365
2012-07-01 to 2013-06-30291,046USD365
2011-07-01 to 2012-06-30255,637USD366

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2013-07-01 to 2014-06-30-145,257USD365
2012-07-01 to 2013-06-3042,806USD365
2011-07-01 to 2012-06-3034,989USD366

Inspect the source

Entity
ELOXX PHARMACEUTICALS, INC. / CIK 0001035354
Captured
2026-09-20T05:15:09.498Z
SEC response SHA-256
b351a9ed06ee3e6f1d738bbdb3852b866526fe561e11a7ffd4a81bc43bb27195

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001035354.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))